OCS Stock Analysis: Oculis Holding Ordinary | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 817m USD | 12M Return: -27.6% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 7.15M
Qual. Beats: 0
Rev. Trend: -69.9%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 5.1 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Oculis Holding AG (OCS) is a Switzerland-based clinical-stage biopharmaceutical company focused on developing topical and neuroprotective treatments for ophthalmic and neurological diseases. The company utilizes its proprietary Optireach technology to enhance drug delivery to both the front and back of the eye, aiming to replace invasive injections with non-invasive eye drops.
The company’s portfolio includes OCS-01, currently in Phase 3 trials for diabetic macular edema, alongside OCS-02 for dry eye disease and OCS-05, a neuroprotective candidate targeting optic neuritis and glaucoma. Biotechnology firms in the ophthalmology sector often face high R&D costs and rigorous regulatory hurdles, as clinical success depends on demonstrating superior efficacy over existing standard-of-care surgical or injectable interventions.
For a detailed breakdown of the companys financial health and pipeline progress, you may find further insights on ValueRay helpful. Founded in 2017 and headquartered in Zug, Oculis operates internationally to address significant unmet needs in vision loss and neuro-ophthalmology.
- OCS-01 Phase 3 clinical trial results for diabetic macular edema
- Regulatory approval timeline for OCS-02 topical biologic in dry eye disease
- Clinical data readouts for OCS-05 neuroprotective agent across multiple indications
- Cash runway and funding requirements for late-stage ophthalmic drug development
- Market adoption of Optireach technology versus traditional ocular drug delivery methods
| Net Income: -95.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.26 > 0.02 and ΔFCF/TA 0.77 > 1.0 |
| NWC/Revenue: 36.2k% < 20% (prev 61.0k%; Δ -24.7k% < -1%) |
| CFO/TA -0.26 > 3% & CFO -62.9m > Net Income -95.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 5.18 > 1.5 & < 3 |
| Outstanding Shares: last quarter (58.9m) vs 12m ago 22.05% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.23% > 50% (prev 0.12%; Δ 0.11% > 0%) |
| Interest Coverage Ratio: -105.3 > 6 (EBIT TTM -84.4m / Interest Expense TTM 801k) |
| A: 0.75 (Total Current Assets 226.4m - Total Current Liabilities 43.7m) / Total Assets 243.3m |
| B: -1.69 (Retained Earnings -412.1m / Total Assets 243.3m) |
| C: -0.38 (EBIT TTM -84.4m / Avg Total Assets 223.7m) |
| D: 4.15 (Book Value of Equity 196.1m / Total Liabilities 47.2m) |
| Altman-Z'' = 1.23 = BB |
| DSRI: 0.30 (Receivables 1.57m/2.56m, Revenue 504k/245k) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.85 (AQ_t 0.06 / AQ_t-1 0.07) |
| SGI: 2.06 (Revenue 504k / 245k) |
| TATA: -0.13 (NI -95.1m - CFO -62.9m) / TA 243.3m) |
| Beneish M = -2.95 (Cap -4..+1) = A |
As of July 08, 2026, the stock is trading at USD 13.56 with a total of 505,344 shares traded. Over the past week, the price has changed by +3.59%, over one month by +26.61%, over three months by -48.64% and over the past year by -27.64%.
Current recommended Stop Loss: 12.30 (which is 9.3% or 1.1 ATR below the current price).
Oculis Holding Ordinary has received a consensus analysts rating of 4.71. Therefore, it is recommended to buy OCS.
- StrongBuy: 5
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 37.7 | 177.9% |
Market Cap CHF = 656.4m (817.1m USD * 0.8034 USD.CHF)
P/S = 727.5607
P/B = 3.3623
Revenue TTM = 504k CHF
EBIT TTM = -84.4m CHF
EBITDA TTM = -83.8m CHF
Long Term Debt = 1.83m CHF (estimated: total debt 2.24m - short term 415k)
Short Term Debt = 415k CHF (from shortTermDebt, last quarter)
Debt = 2.24m CHF (from shortLongTermDebtTotal, last quarter) (leases 2.25m already included)
Net Debt = -219.1m CHF (calculated: Debt 2.24m - CCE 221.4m)
Enterprise Value = 437.3m CHF (656.4m + Debt 2.24m - CCE 221.4m)
Interest Coverage Ratio = -105.3 (Ebit TTM -84.4m / Interest Expense TTM 801k)
EV/FCF = -6.92x (Enterprise Value 437.3m / FCF TTM -63.2m)
FCF Yield = -14.45% (FCF TTM -63.2m / Enterprise Value 437.3m)
FCF Margin = -12.5k% (FCF TTM -63.2m / Revenue TTM 504k)
Net Margin = -18.9k% (Net Income TTM -95.1m / Revenue TTM 504k)
Gross Margin = unknown ((Revenue TTM 504k - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 1.80 (Enterprise Value 437.3m / Total Assets 243.3m)
Interest Expense / Debt = 35.76% (Interest Expense 801k / Debt 2.24m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -66.7m (EBIT -84.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.18 (Total Current Assets 226.4m / Total Current Liabilities 43.7m)
Debt / Equity = 0.01 (Debt 2.24m / totalStockholderEquity, last quarter 196.1m)
Debt / EBITDA = 2.61 (negative EBITDA) (Net Debt -219.1m / EBITDA -83.8m)
Debt / FCF = 3.47 (negative FCF - burning cash) (Net Debt -219.1m / FCF TTM -63.2m)
Total Stockholder Equity = 166.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -42.49% (Net Income -95.1m / Total Assets 243.3m)
RoE = -57.09% (Net Income TTM -95.1m / Total Stockholder Equity 166.5m)
RoCE = -50.12% (EBIT -84.4m / Capital Employed (Equity 166.5m + L.T.Debt 1.83m))
RoIC = -33.34% (negative operating profit) (NOPAT -66.7m / Invested Capital 199.9m)
WACC = 8.25% (E(656.4m)/V(658.7m) * Re(8.18%) + D(2.24m)/V(658.7m) * Rd(35.76%) * (1-Tc(0.21)))
Discount Rate = 8.18% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 94.39 | Cagr: 23.31%
[DCF] Fair Price = unknown (Cash Flow -63.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.64 | # QB: 0
Revenue Correlation: -69.89 | Revenue CAGR: -30.57% | SUE: -0.53 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.39 | Chg30d=+11.00% | Revisions=+50% | Analysts=9
EPS next Quarter (2026-09-30): EPS=-0.41 | Chg30d=+9.89% | Revisions=+30% | Analysts=9
EPS current Year (2026-12-31): EPS=-1.77 | Chg30d=-1.22% | Revisions=-18% | GrowthEPS=+6.5% | GrowthRev=-31.4%
EPS next Year (2027-12-31): EPS=-1.64 | Chg30d=+2.94% | Revisions=+30% | GrowthEPS=+7.5% | GrowthRev=+862.9%
[Analyst] Revisions Ratio: +28% (up=19, down=10)